- Conditions
- Age Related Macular Degeneration
- Interventions
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Retinopathy, Diabetes Complications
- Interventions
- Laser Treatment, PF-04523655 high, PF-04523655 middle, PF-04523655 low
- Procedure · Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 26
- States / cities
- Mesa, Arizona • Meza, Arizona • Peoria, Arizona + 20 more